Document Detail

Effect of bupivacaine on sevoflurane-induced preconditioning in isolated rat hearts.
MedLine Citation:
PMID:  20816812     Owner:  NLM     Status:  In-Process    
Volatile anesthetics protect the heart against ischemia-reperfusion injury. As an adjunct to general anesthesia, local and regional application of bupivacaine is often used. However, systemic plasma levels of bupivacaine might be cardiodepressant and interfere with sevoflurane-induced cardioprotection. Effects of bupivacaine on sevoflurane-induced cardioprotection were assessed in isolated Langendorff-perfused rat hearts subjected to 35 min of global ischemia followed by 60 min reperfusion. Hearts (n=40) were randomized to different groups: 1. Control; 2. Bupivacaine: addition of 0.125 or 1.0 μg/ml bupivacaine to the perfusate for 40 min prior to ischemia-reperfusion; 3. Sevoflurane: preconditioning induced by three times 5-min episodes of sevoflurane (2.5 vol.%) prior to ischemia-reperfusion; 4. Bupivacaine-sevoflurane: combined application of bupivacaine and sevoflurane. After ischemia-reperfusion, cardioprotection was assessed from infarct size and recovery of ventricular function, and phosphorylation levels of glycogen synthase kinase 3β (GSK3β) and 5'AMP activated protein kinase (AMPK) were determined. Infarct size was reduced in the sevoflurane and bupivacaine-sevoflurane groups (Sevo: 23±7% and Bupi-Sevo: 23±5% vs. Control: 59±6%, P<0.05). In the bupivacaine group infarct size was reduced as well (34±3%). In the sevoflurane and bupivacaine-sevoflurane groups the recovery of left ventricular function (+dP/dt) was improved (Sevo: 59±2% and Bupi-Sevo: 59±2% vs. Control: 47±3%, P<0.05), but not in the bupivacaine group (48±3%). AMPK and GSK3β phosphorylation were increased by sevoflurane but not by bupivacaine. Sevoflurane-induced cardioprotection was not affected by bupivacaine in the non-cardiotoxic range. Bupivacaine alone also reduced infarct size. Both anesthetics activated different signaling kinases, indicating the existence of different cardioprotective intracellular signaling cascades.
R Arthur Bouwman; M Jumoke A Vreden; Nazha Hamdani; Lisan E J Wassenaar; Lonneke Smeding; Stephan A Loer; Ger J M Stienen; Regis R Lamberts
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-09-09
Journal Detail:
Title:  European journal of pharmacology     Volume:  647     ISSN:  1879-0712     ISO Abbreviation:  Eur. J. Pharmacol.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-04     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  1254354     Medline TA:  Eur J Pharmacol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  132-8     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Elsevier B.V. All rights reserved.
Department of Anesthesiology, Institute for Cardiovascular Research (ICaR-VU), VU University Medical Center (VUMC), Amsterdam, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Pachymic acid stimulates glucose uptake through enhanced GLUT4 expression and translocation.
Next Document:  HZ08, a great regulator to reverse multidrug resistance via cycle arrest and apoptosis sensitization...